These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 28689768)

  • 1. Use of bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Szulc P
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):908-923. PubMed ID: 28689768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone turnover: Biology and assessment tools.
    Szulc P
    Best Pract Res Clin Endocrinol Metab; 2018 Oct; 32(5):725-738. PubMed ID: 30449551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis.
    Lorentzon M; Branco J; Brandi ML; Bruyère O; Chapurlat R; Cooper C; Cortet B; Diez-Perez A; Ferrari S; Gasparik A; Herrmann M; Jorgensen NR; Kanis J; Kaufman JM; Laslop A; Locquet M; Matijevic R; McCloskey E; Minisola S; Pikner R; Reginster JY; Rizzoli R; Szulc P; Vlaskovska M; Cavalier E
    Adv Ther; 2019 Oct; 36(10):2811-2824. PubMed ID: 31440982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
    J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.
    Vasikaran S; Eastell R; Bruyère O; Foldes AJ; Garnero P; Griesmacher A; McClung M; Morris HA; Silverman S; Trenti T; Wahl DA; Cooper C; Kanis JA;
    Osteoporos Int; 2011 Feb; 22(2):391-420. PubMed ID: 21184054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
    Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
    Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy.
    Reginster JY; Collette J; Neuprez A; Zegels B; Deroisy R; Bruyere O
    Bone; 2008 May; 42(5):832-6. PubMed ID: 18316258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.
    Szulc P; Naylor K; Hoyle NR; Eastell R; Leary ET;
    Osteoporos Int; 2017 Sep; 28(9):2541-2556. PubMed ID: 28631236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
    Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.
    Hannon R; Blumsohn A; Naylor K; Eastell R
    J Bone Miner Res; 1998 Jul; 13(7):1124-33. PubMed ID: 9661076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current use of bone turnover markers in the management of osteoporosis.
    Brown JP; Don-Wauchope A; Douville P; Albert C; Vasikaran SD
    Clin Biochem; 2022; 109-110():1-10. PubMed ID: 36096182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis.
    Delmas PD; Munoz F; Black DM; Cosman F; Boonen S; Watts NB; Kendler D; Eriksen EF; Mesenbrink PG; Eastell R;
    J Bone Miner Res; 2009 Sep; 24(9):1544-51. PubMed ID: 19338427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biochemical markers of bone turnover : clinical usefulness in osteoporosis].
    Garnero P; Delmas PD
    Ann Biol Clin (Paris); 1999; 57(2):137-48. PubMed ID: 10210740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate.
    Middleton ET; Steel SA; Aye M; Doherty SM
    J Bone Miner Res; 2010 Mar; 25(3):455-62. PubMed ID: 20201000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis.
    Naylor KE; McCloskey EV; Jacques RM; Peel NFA; Paggiosi MA; Gossiel F; Walsh JS; Eastell R
    Osteoporos Int; 2019 Apr; 30(4):917-922. PubMed ID: 30613868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.